Benzinga - by Lisa Levin, Benzinga Editor.
Gainers
- AgileThought, Inc. (NASDAQ: AGIL) rose 96.5% to $0.3046 in pre-market trading after falling 17% on Tuesday.
- Digital Brands Group, Inc. (NASDAQ: DBGI) shares gained 57.9% to $13.33 in pre-market trading. DBGI effected a 1-for-25 reverse stock split on Tuesday.
- NanoVibronix, Inc. (NASDAQ: NAOV) shares climbed 49% to $2.18 in pre-market trading after the company reported outcomes from a UroShield study conducted at the University of Southampton in the U.K.
- Tingo Group, Inc. (NASDAQ: TIO) shares rose 42.4% to $1.21 in pre-market trading. Tingo Group announced completion of investigation into allegations made against the company in short-seller report and issued its response.
- Top KingWin Ltd. (NASDAQ: TCJH) shares gained 30.5% to $1.7093 in pre-market trading after gaining 8% on Tuesday.
- Aravive, Inc. (NASDAQ: ARAV) shares rose 24.4% to $0.1489 in pre-market trading after gaining over 6% on Tuesday.
- 1847 Holdings LLC (NYSE: EFSH) gained 18.3% to $0.1150 in pre-market trading after the company announced plans to acquire a premier consumer products company with revenue in excess of $20 million and positive EBITDA in 2022.
- Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 17.6% to $1.20 in pre-market trading after falling 7% on Tuesday.
- Arcadia Biosciences, Inc. (NASDAQ: RKDA) shares surged 14.3% to $4.00 in pre-market trading.
- Globalstar, Inc. (NYSE: GSAT) rose 13% to $1.4799 in pre-market trading. Globalstar shares gained over 23% on Tuesday after the company announced it appointed Dr. Paul Jacobs as CEO and announced an agreement to license XCOM Labs technology.
- Outlook Therapeutics, Inc. (NASDAQ: OTLK) fell 78.4% to $0.3050 in pre-market trading after the company received an FDA complete response letter regarding ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat Wet Age-Related Macular Degeneration (Wet AMD).
- FibroGen, Inc. (NASDAQ: FGEN) shares fell 24.2% to $0.9699 in pre-market trading after the company reported topline results from LELANTOS-2, a Phase 3 clinical study of pamrevlumab in ambulatory duchenne muscular dystrophy.
- MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) fell 22.5% to $19.34 in pre-market trading after posting fourth-quarter results.
- Ambarella, Inc. (NASDAQ: AMBA) fell 19.7% to $60.75 in pre-market trading after the company issued third-quarter revenue guidance below estimates.
- Genius Group Limited (NYSE: GNS) shares fell 17.7% to $1.39 in pre-market trading after declining over 26% on Tuesday.
- TD Holdings, Inc. (NASDAQ: GLG) fell 14.4% to $0.2534 in pre-market trading after dipping 72% on Tuesday.
- Tivic Health Systems, Inc. (NASDAQ: TIVC) shares fell 12.7% to $2.60 in pre-market trading after jumping over 53% on Tuesday.
- VAALCO Energy, Inc. (NYSE: EGY) fell 12.4% to $4.10 in pre-market.
- LENSAR, Inc. (NASDAQ: LNSR) fell 11.7% to $3.09 in pre-market trading.
- OKYO Pharma Limited (NASDAQ: OKYO) fell 7% to $2.84 in pre-market trading. OKYO Pharma achieved 90% enrollment in 240-patient Phase 2 clinical trial of OK-101 to treat dry eye disease.
Now Read This: Top 5 Consumer Stocks That May Rocket Higher This Quarter
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.